WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Serum Parathyroid Hormone and the Risk of Mineral Bone Deterioration in Individuals with Chronic Renal Disease

Mr. Kashif Naem Siddiqqi[1], Prof. Dr. Jaya Jain[2]

[1]Research Scholar, Malwanchal University, Indore
[2]Research Supervisor, Malwanchal University, Indore

Introduction

The clinical condition known as "chronic kidney disease (CKD)-mineral and bone disorder (MBD)" describes the development of a systemic disorder of mineral and bone metabolisms as a consequence of CKD. This disorder may take the form of any one of the following or a combination of them: Vitamin D deficiency; calcium deficiency; phosphorus deficiency; parathyroid hormone (PTH) deficiency; defects in bone formation and repair; and calcium deposits in the vessels or other soft tissues The majority of patients with CKD will have no noticeable symptoms from their bone condition. During the later stages of MBD, symptoms become apparent. Most individuals with chronic kidney disease (CKD) have secondary hyperparathyroidism (SHPT), characterised by an increase in PTH. Patients in the earlier stages of chronic kidney disease (CKD), when medication might offer the most effect, frequently fail to have SHPT diagnosed and are only minimally treated. Calcium, phosphorus, and the calcium-x-phosphorus product tend to rise after SHPT has reached an uncontrolled stage. Disorders of metabolic bone with rapid turnover in chronic renal disease The evolution of SHPT led to the emergence of high-turnover bone disease. Hyperplasia of the parathyroid glands and elevated PTH levels in the blood have been seen at an early stage in the progression of CKD for quite some time. A chronic kidney disease risk factor is low bone turnover (adynamic bone disease). Low-turnover bone disease is characterised by an exceedingly slow rate of bone creation and is often seen in people with renal illness, particularly those on dialysis. Skeletal resistance to the actions of PTH, hypocalcemia, phosphorus retention, decreased calcitriol levels, intrinsic alterations within the parathyroid gland that lead to increased PTH secretion, and increased parathyroid growth

The goal of this study was to find a noninvasive way to measure iPTH levels in the blood of CKD patients so that early cases of MBD could be found. Serum phosphorus, calcium, parathyroid hormone (PTH), and alkaline phosphatase (AP) should be monitored in patients with an eGFR of 60 mL/min/1.73 m2 based on the presence and magnitude of abnormalities and the rate of CKD progression, according to the kidney disease improving global outcomes (KDIGO) guidelines.

Methodology

The Index Medical College hospital's Ethical Review Board gave its clearance for this observational research. The participants in the current study were hospitalised between March 2018 and March 2019 and were cared for in the hospital's Dialysis Unit, Nephrology Outpatient Clinic, and medicine wards. One hundred individuals with CKD, either on hemodialysis or not, were included in the research.

Acceptance criteria

The chronic kidney disease recommendations from the Kidney Disease: Improving Global Outcomes initiative state: "an estimated glomerular filtration rate (eGFR) of 50 mL/min/1.73 m2 or below." If an ultrasound reveals that your kidney is smaller than 8 centimetres in diameter, or if you have lost corticomedullary differentiation and have increased echogenicity, you may have a condition called contracted kidney. Patients with autosomal dominant polycystic kidney disease, diabetic nephropathy, and amyloidosis often have significantly enlarged kidneys.

Criteria for omission

Urinary tract or male reproductive system cancer, also known as genitourinary cancer, acute kidney injury, and acute on chronic kidney disease.
Clinical histories, physical examinations, and blood tests including blood urea level (BUL), serum creatinine level, serum electrolytes, calcium,

phosphorus, alkaline phosphatase (ALP), and iPTH were performed on each patient. All patients had abdominal and pelvic ultrasonography. Conventional radio-immunoassay was used to measure PTH levels; this method identifies the middle and COOH terminal fragments, both of which are physiologically active. When the kidneys aren't working properly, even the inert bits build up. The intact PTH is the gold standard for diagnosing SHPT because of its excellent specificity and sensitivity. Clinical, biochemical, and imaging findings all contributed to the diagnosis of MBD in our patients.Potential correlations (CIs) were looked into using Chi-square tests, as well as sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) with 95% CIs.

Results

Of the total number of patients, 30% were between the ages of 40 and 50, 42% had CKD for less than a year, 52% had it for between a year and four years, and 20% had it for more than four years. This finding implies that the duration of CKD was unrelated to the presence of MBD. Eighty-three percent of individuals with CKD were found to have MBD, whereas 22 percent were found to be MBD-free. Of these 40 patients, 68% were receiving maintenance hemodialysis, and 35% were either not receiving hemodialysis at all or had never had it before. Forty-six patients out of a total of 100 hemodialysis patients with CKD had MBD, whereas only six did not. 46 out of 100 people with CKD who had never received hemodialysis were MBD positive, whereas 8 were MBD negative.

The majority of patients (61%) with CKD had a mix of hypertension and diabetic nephropathy. Serum iPTH levels were elevated in 96 out of 100 CKD patients. MBD was present in 81.3% of individuals with elevated iPTH. 7 % of patients with normal iPTH levels developed MBD, 2 = 5.26,(P = 0.0), sensitivity -96% (95% CI: 88.9, 98.9), specificity -17.43%, PPV-78.5%, and(, NPV -74.3s present in 81.3% of individuals with elevated iPTH. 7% of patients with normal iPTH levels developed MBD, 2 = 5.26, P = 0.02, sensitivity -96% (95% CI: 88.9, 98.9), specificity -17.43%, PPV -78.5%, and NPV -74.39%. . Those with MBD had an iPTH mean and standard deviation (SD) o159 (36.7.9) (Z = 8.12, P 0.0001), whereas those without MBD had a mean and SD of 98.8 (Z = -1.9, P > 0.0001). (24.9). As measured by MBD, there was a statistically significant correlation between elevated iPTH levels and elevated BUL in the study population.

According to MBD, there was no correlation between the study group's levels of haemoglobin, creatinine, uric acid, phosphorous, calcium, or alanine aminotransferase (ALP).

Conclusion

As a result, it is possible to conclude that elevated blood parathyroid levels were sensitive but not specific for detecting MBD in CKD.To improve the diagnosis and treatment of CKD-MBD, gaps in the evidence are highlighted by the evidence-based KDIGO recommendations. Multiple biochemical markers, patient demographics, and extracomorbidities all interact in this exceedingly complicated illness. Thus, there are no blanket treatment regimens that can be used for all individuals with CKD-MBD. Instead, doctors need to customise their care for each patient by monitoring a variety of CKD-MBD indicators and responding accordingly.

Reference

1) Felsenfeld AJ, Rodríguez M, Aguilera-Tejero E: Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism. Clin J Am Soc Nephrol 2: 1283–1305, 2007pmid:17942777

2) Kraenzlin ME, Meier C: Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol 7: 647–656, 2011

3) Lamb EJ, Vickery S, Ellis AR: Parathyroid hormone, kidney disease, evidence and guidelines. Ann Clin Biochem 44(Pt 1): 1–4, 2007

4) Massry SG: Is parathyroid hormone a uremic toxin? Nephron 19: 125–130, 1977pmid:895963

5) Rodriguez M, Lorenzo V: Parathyroid hormone, a uremic toxin. Semin Dial 22: 363–368, 2009

6) Sprague SM: Renal bone disease. CurrOpin Endocrinol Diabetes Obes 17: 535–539, 2010

7) Covic A, Kanbay M, Voroneanu L, Turgut F, Serban DN, Serban IL, Goldsmith DJ: Vascular calcification in chronic kidney disease. Clin Sci (Lond) 119:111–121, 2010.

8) Ketteler M, Rothe H, Krüger T, Biggar PH, Schlieper G: Mechanisms and treatment of extraosseous calcification in chronic kidney disease. Nat Rev Nephrol 7: 509–516, 2011

9) Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease:

Improving Global Outcomes (KDIGO). Kidney Int 69: 1945–1953, 2006pmid:16641930

10) London G, Coyne D, Hruska K, Malluche HH, Martin KJ: The new kidney disease: Improving global outcomes (KDIGO) guidelines—expert clinical focus on bone and vascular calcification. Clin Nephrol 74: 423–432, 2010pmid:21084045

11) Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31–38, 2007